Business Wire

CGTN

19.8.2020 14:12:04 CEST | Business Wire | Press release

Share
CGTN: Xi Jinping conducts inspection tour in flood-hit Anhui Province

Chinese President Xi Jinping arrived in east China's Anhui Province for an inspection tour on Tuesday.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005372/en/

Xi, also general secretary of the Communist Party of China Central Committee, visited the floodgate of the Wangjiaba Dam on the Huaihe River and other flood-hit areas in Funan County, Fuyang City. He also went to a "zhuangtai," a residential structure built on raised ground at a higher elevation that functions as a haven from river floods.

Since June, Anhui has been ravaged by floods and landslides caused by incessant heavy rains.

The president also met with local officials and residents and learned about flood prevention and disaster relief work and the progress of recovery efforts.

This is President Xi's latest inspection tour this year, following his visits to Yunnan Province , Beijing Municipality , Hubei Province , Zhejiang Province , Shaanxi Province , Shanxi Province , Ningxia Hui Autonomous Region and Jilin Province .

People-centered efforts

"I have always been concerned about the people in flood-stricken areas," Xi said while meeting locals, adding that he felt ease after seeing villagers had a place to live and had restarted production.

Severe rainstorms have hit many regions in China this summer, triggering flooding of rivers. According to the Ministry of Emergency Management (MEM), 54.8 million people in 27 provincial-level regions have been affected.

Chinese leaders have called for unrelenting efforts to ensure the safety of people's lives and property.

During a CPC leadership meeting on July 17, President Xi stressed putting people's lives and property first and taking more forceful measures to do well in flood control and relief work.

China has made all-out efforts in flood control and disaster relief with massive mobilization, evacuations and a top-level emergency response in several hard-hit provinces.

Through the nationwide joint efforts, the MEM said, the number of deaths and missing due to floods fell by 53.9 percent from with the national average of the past five years. The number of evacuated people increased by 36.7 percent, the ministry added.

Enhance capabilities to cope with natural disasters

Noting that China has fought against natural disasters for thousands of years, Xi on Tuesday also urged respect for nature, harmony between humans and nature and efforts to improve capabilities to cope with natural disasters.

"We should modernize our ability to prevent and combat natural disasters in our effort to build a modern socialist country in an all-round way," Xi added.

Hailed as the "most important floodgate on the Huaihe River," the floodgate of the Wangjiaba Dam sets a good example of China's flood preparation.

The floodgate, built in 1953 was opened for the 16th time on July 20 to store water, intercepting 375 million cubic meters of potential floodwater by July 23 when it was closed.

The CPC leadership meeting on July 17 also stressed that China needs to comprehensively enhance its disaster prevention capability and will include capacity building on disaster prevention in its 14th Five-Year Plan covering the period 2021-2025.

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye